Navigation Links
Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
Date:7/30/2009

ed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R)( )(galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R)( )(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.B
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. 90 Brain Fitness Patents for Posit Science
2. Misonix Announces the Purchase of Patents From ProRhythm, Inc.
3. Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
4. Impliant Granted Two New U.S. Patents and Successfully Defends European Patent Opposition Case
5. CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents
6. ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics
7. ACLU Challenges Patents on Breast Cancer Genes
8. MMR Information Systems, Inc. Announces 250,000 Membership Milestone and Granting of International Patents
9. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
10. United States Patent Office Rejects KCIs Patents
11. ALSIUS CORPORATION PREPARED TO INVALIDATE ZOLL TEMPERATURE MANAGEMENT PATENTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... 2011 Studies show drinking V8 100% vegetable juice may be ... and may help them manage their weight two areas ... Guidelines for Americans. 1 A study conducted by ... drank one, 8-ounce glass of vegetable juice each day, as ...
... , THURSDAY, Feb. 3 (HealthDay News) -- Daily electronic ... doctors better understand the condition, a new study shows. ... digital assistant (PDA) device. The patients used their PDA ... issues three times a day for 30 days. ...
... DALLAS Feb. 3, 2011 UT Southwestern Medical ... a national network that conducts clinical trials aimed at ... 100 community treatment providers and academic medical centers throughout ... Institute on Drug Abuse,s Clinical Trials Network (CTN). The ...
... Feb. 2 (HealthDay News) -- Researchers report that DNA analysis ... rare vascular disease, along with its genetic cause. As ... England Journal of Medicine , the debilitating, painful and progressive ... the hands and feet of patients, and in the vascular ...
... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, ... can help predict a daughter,s chances of not only having ... attack, new research shows. "Our new study shows that ... said Dr. Amitava Banerjee, a clinical research associate at the ...
... for ways to see dangerous blood clots before they ... School of Medicine in St. Louis report that they ... visible to a new kind of X-ray technology. ... cardiologist at Barnes-Jewish Hospital, these nanoparticles will take the ...
Cached Medicine News:Health News:Research suggests V8 100% vegetable juice can help people meet key dietary guidelines 2Health News:Researchers lead search for better drug-addiction treatments 2Health News:Scientists Discover Rare Vascular Disease 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 3Health News:New nanoparticles make blood clots visible 2Health News:New nanoparticles make blood clots visible 3
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
(Date:10/20/2014)... 20, 2014 Norgine B.V. today ... low volume bowel preparation, NER1006, presented at the 79 ... of Gastroenterology (ACG), Philadelphia, PA , ... weight and co-primary endpoint of cleansing success. The study ... MOVIPREP ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Positive preclinical,data was presented by Nektar ... for its,lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which ... model of colorectal,cancer when co-administered with bevacizumab. ... (AACR) Annual Meeting 2008 in San Diego,California, ...
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... in patients with non-small cell lung cancer has ... multi-center, monotherapy,study of KOS-1584 in patients with measurable ... previously received only one prior,chemotherapy regimen. The primary ...
Cached Medicine Technology:Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 2Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 3Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 4Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 5Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 2Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 3Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer 4
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: